Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Wedbush reaffirmed an Outperform rating and a $350 price target for Apple following the company’s fiscal first-quarter 2026 results. The quarter featured notable iPhone strength, particularly in China, and guidance that outpaces Street expectations, while analysts highlight an uncounted AI premium and elevated valuation multiples.
UBS maintained a Neutral rating and a $19.00 price target on Energizer Holdings Inc. (ENR) ahead of the company's fiscal first-quarter results on February 5. The firm projects Q1 EPS of $0.25, noting pressures from difficult year-ago comparisons tied to storm-driven demand and early display shipment headwinds. Despite a low P/E and a sizable divide…
Rosenblatt Securities raised its 12-month price target for Apple to $267 from $250 while maintaining a Neutral rating. The adjustment follows a fiscal first-quarter 2026 beat driven by stronger-than-expected iPhone demand and improved gross margins, even as Rosenblatt and other firms weigh valuation and potential margin pressures.
Mizuho increased its 12-month price target for Eastman Chemical (EMN) from $68.00 to $75.00 while retaining an Outperform rating. The lift in the target reflects higher market and peer valuation multiples even as the company reported softer fourth-quarter 2025 operating results and issued conservative near-term EPS guidance amid macro uncertainty.
Rosenblatt Securities reduced its price target for Elastic N.V. (ESTC) to $110 from $130 but retained a Buy rating, pointing to recent comparable multiple compression and macroeconomic concerns affecting enterprise software. The stock trades near its 52-week low, while the company has announced product advances including Agent Builder and AWS-focus…
Wedbush has reaffirmed an Outperform rating and a $340.00 price target for Amazon.com (AMZN) ahead of the company’s fourth-quarter earnings report scheduled for February 5. The firm raised its operating income estimates, highlighted accelerating demand and capacity additions at Amazon Web Services (AWS), and said continued strong AWS performance co…
Bernstein SocGen Group raised its price objective for SanDisk to $1,000 from $580 and kept an Outperform rating after the company reported second-quarter revenue and non-GAAP EPS that beat consensus. Management's third-quarter revenue and margin guidance drove the analyst's sharper outlook and prompted similar target increases from several peers, w…
D. Boral Capital lowered its rating on Quince Therapeutics Inc. (QNCX) from Buy to Hold after the company reported negative Phase 3 results for its eDSP program in Ataxia-Telangiectasia. The stock plunged sharply, management has stopped clinical development of eDSP, and the company is pivoting toward conserving cash and evaluating strategic options…
Preliminary data from the national statistics institute show Mexico's economy grew 0.8% in the fourth quarter of 2025, outpacing consensus and reversing a contraction in Q3. On an annual basis Q4 GDP rose 1.6%, and the full-year expansion for 2025 was 0.5%, exceeding central bank and analyst forecasts. Agriculture was the strongest performing secto…
Bank of America reiterated a Buy rating on Snowflake, calling the AI-focused data cloud vendor one of the fastest growing stories in software. The bank raised its price target to $275 and said Snowflake is well positioned to benefit from rising enterprise spending on data analytics and AI, though the stock trades at a significant premium to peers.
Regeneron Pharmaceuticals reported fourth-quarter adjusted earnings that exceeded analyst expectations, driven by robust demand for the eczema medication Dupixent. While Dupixent sales climbed substantially, Eylea revenue fell sharply amid competitive pressures and regulatory delays tied to a manufacturing facility. Sanofi warned that Dupixent will…
Goldman Sachs began coverage of Kerry Group with a buy recommendation, assigning a 12-month target price of €95 versus an initiation price of €73.45 and highlighting a recent multi-year portfolio transformation that left Kerry as a pure-play ingredients supplier. The report points to improved margins after the divestiture of Dairy Ireland, a heavy …
H.C. Wainwright raised its price target on Protagonist Therapeutics to $117.00 from $80.00 and retained a Buy rating, citing the commercial and financial implications of a rusfertide New Drug Application submitted by Takeda and Protagonist. The firm expects the company will likely opt out of a profit-sharing arrangement, unlocking substantial upfro…
H.C. Wainwright increased its price target for Praxis Precision Medicines Inc. (PRAX) to $1,245 from $340 while keeping a Buy rating, citing higher peak sales expectations for ulixacaltamide and relutrigine. The firm highlights relutrigine as a potential broad-use therapy with projected peak sales of $6.8 billion and points to forthcoming clinical …
Mizuho lowered its price target on Royal Caribbean Cruises (RCL) to $379 from $381 but maintained an Outperform rating after the company reported a weak first-quarter performance in the Caribbean that appears contained. The firm noted several constructive signals, including better-than-expected full-year cost and yield guidance, higher EPS guidance…
H.C. Wainwright increased its price target on Perspective Therapeutics Inc (NYSE: CATX) to $12.00 from $10.00 and kept a Buy rating, citing clinical data and a reduced competitive field following Sanofi's deprioritization of its SSTR2-targeted radioimmunotherapy. Perspective's shares traded at $4.26 after a one-week gain of 57.2%, and analyst targe…
H.C. Wainwright reduced its fair-value target for Inuvo Inc. (INUV) to $6.00 from $10.00 while keeping a Buy rating after the company reported preliminary fourth-quarter 2025 revenue that materially missed consensus. Management has signaled a strategic shift toward a technology-focused, higher-margin platform and installed Rob Buchner as Chairman a…
H.C. Wainwright raised its price objective on Alnylam Pharmaceuticals to $510 from $470 and kept a Buy rating, pointing to the scaling of the company’s TTR franchise and its multi-year strategic roadmap as drivers. The firm adjusted forward estimates to reflect post-launch normalization, higher sustained R&D spending and conservative margin assumpt…
Mizuho lowered its price target for Tractor Supply Company to $58 from $65 while keeping an Outperform rating, pointing to a "clear shift in management’s tone" on the rural economy and noting renewed promotional activity. The move follows a fourth-quarter 2025 earnings shortfall and a string of target cuts from peer research firms.
Needham upgraded Globus Medical (NYSE: GMED) from Hold to Buy and set a $112 price target after the company released preliminary fourth-quarter 2025 revenue figures. The firm highlighted margin expansion -- citing an estimated 20% EBITDA margin at Nevro and further margin gains in 2026 -- as a driver of upside to 2026 EPS, while other analysts also…
H.C. Wainwright lowered its price objective on Nouveau Monde Graphite Inc. (NMG) to $5.50 from $7.50 while retaining a Buy rating. The firm attributed the reduction primarily to dilution from a recent equity raise and to a revised first-production estimate now expected in the first half of 2028. The revised discounted cash flow analysis produces a …
H.C. Wainwright increased its price objective for DRDGOLD Ltd. (NYSE: DRD) to $46.50 from $36.25 while retaining a Buy recommendation. The firm pointed to recent gold price strength, an upgraded NAV multiple, and continued investor interest in DRDGOLD’s Vision 2028 Initiative as the bases for the change. Market data show the stock has risen sharply…
Morgan Stanley forecasts the euro-dollar rate to climb to 1.23 in the second quarter of 2026, attributing recent dollar weakness to atypical catalysts rather than interest-rate gaps. The bank cautions that while a firmer euro boosts European asset returns in constant currency terms, it will weigh on local earnings through translation effects, reduc…
Canaccord Genuity has reiterated a Buy rating on Stryker (SYK) and assigned a $435 price target following the company’s robust quarterly results. The target implies notable upside from the stock's current level, while other analysts' targets span a wide range. Stryker reported double-digit growth across multiple business segments, strengthened its …
SoFi Technologies reported a jump in fourth-quarter profit driven by robust loan demand and rapid expansion of fee-based financial services. The fintech's financial services revenue climbed sharply, while total loan originations reached a record $10.5 billion. CEO Anthony Noto said member credit performance remained in line with expectations, and w…
